Malaria Vaccine Clinical Trials: What's on the Horizon

Overview

Journal Curr Opin Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2015 Jul 15

PMID 26172291

Citations 12

Authors

Alberto Moreno

Chester Joyner

Affiliations

Soon will be listed here.

Abstract

Significant progress toward a malaria vaccine, specifically for Plasmodium falciparum, has been made in the past few years with the completion of numerous clinical trials. Each trial has utilized a unique combination of antigens, delivery platforms, and adjuvants, which has provided the research community with a wealth of critical information to apply towards the development of next generation malaria vaccines. Despite the progress toward a P. falciparum vaccine, P. vivax vaccine research requires more momentum and additional investigations to identify novel vaccine candidates. In this review, recently completed and ongoing malaria vaccine clinical trials as well as vaccine candidates that are in the development pipeline are reviewed. Perspectives for future research using post-genomic mining, nonhuman primate models, and systems biology are also discussed.

Citing Articles

Characterization of T and B cell epitopes in PvCyRPA by studying the naturally acquired immune response in Brazilian Amazon communities.

Soares I, Baptista B, da Silva Matos A, Rodrigues-da-Silva R, Kujbida Junior M, Albrecht L Sci Rep. 2024; 14(1):27343.

PMID: 39521783 PMC: 11550457. DOI: 10.1038/s41598-024-72671-x.

Natural Infection Stimulates Human Antibodies to MSP1 Epitopes Identified in Mice Infection Models upon Non-Natural Modified Peptidomimetic Vaccination.

Rodriguez Z, Melo F, Torres A, Agrawal N, Cortes-Vecino J, Lozano J Molecules. 2023; 28(6).

PMID: 36985500 PMC: 10057838. DOI: 10.3390/molecules28062527.

Systems biology of malaria explored with nonhuman primates.

Galinski M Malar J. 2022; 21(1):177.

PMID: 35672852 PMC: 9172618. DOI: 10.1186/s12936-022-04199-2.

A comprehensive study of epitopes and immune reactivity among Plasmodium species.

Kalkal M, Kalkal A, Dhanda S, Das E, Pande V, Das J BMC Microbiol. 2022; 22(1):74.

PMID: 35277125 PMC: 8913861. DOI: 10.1186/s12866-022-02480-7.

The Search of a Malaria Vaccine: The Time for Modified Immuno-Potentiating Probes.

Lozano J, Rodriguez Parra Z, Hernandez-Martinez S, Fernanda Yasnot-Acosta M, Rojas A, Marin-Waldo L Vaccines (Basel). 2021; 9(2).

PMID: 33540947 PMC: 7913233. DOI: 10.3390/vaccines9020115.

References

Clausen T, Christoffersen S, Dahlback M, Langkilde A, Jensen K, Resende M . Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria. J Biol Chem. 2012; 287(28):23332-45. PMC: 3390611. DOI: 10.1074/jbc.M112.348839. View

Crosnier C, Bustamante L, Bartholdson S, Bei A, Theron M, Uchikawa M . Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature. 2011; 480(7378):534-7. PMC: 3245779. DOI: 10.1038/nature10606. View

Lumsden J, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S . Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun. 2011; 79(9):3492-500. PMC: 3165477. DOI: 10.1128/IAI.05257-11. View

Krotoski W, Garnham P, BRAY R, Krotoski D, Killick-Kendrick R, Draper C . Observations on early and late post-sporozoite tissue stages in primate malaria. I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24 hours after infection. Am J Trop Med Hyg. 1982; 31(1):24-35. View

Li S, Nakaya H, Kazmin D, Oh J, Pulendran B . Systems biological approaches to measure and understand vaccine immunity in humans. Semin Immunol. 2013; 25(3):209-18. PMC: 3797847. DOI: 10.1016/j.smim.2013.05.003. View

Epstein J, Richie T . The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review. Curr Opin Infect Dis. 2013; 26(5):420-8. DOI: 10.1097/QCO.0000000000000002. View

Wertheimer S, Barnwell J . Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein. Exp Parasitol. 1989; 69(4):340-50. DOI: 10.1016/0014-4894(89)90083-0. View

Laurens M, Billingsley P, Richman A, Eappen A, Adams M, Li T . Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One. 2013; 8(7):e68969. PMC: 3712927. DOI: 10.1371/journal.pone.0068969. View

Polhemus M, Magill A, Cummings J, Kester K, Ockenhouse C, Lanar D . Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine. 2007; 25(21):4203-12. DOI: 10.1016/j.vaccine.2007.03.012. View

10.

Proietti C, Doolan D . The case for a rational genome-based vaccine against malaria. Front Microbiol. 2015; 5:741. PMC: 4302942. DOI: 10.3389/fmicb.2014.00741. View

11.

Galinski M, Meyer E, Barnwell J . Plasmodium vivax: modern strategies to study a persistent parasite's life cycle. Adv Parasitol. 2013; 81:1-26. DOI: 10.1016/B978-0-12-407826-0.00001-1. View

12.

Creech C, Dekker C, Ho D, Phillips S, Mackey S, Murray-Krezan C . Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum Vaccin Immunother. 2013; 9(12):2548-57. PMC: 4162066. DOI: 10.4161/hv.26038. View

13.

. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014; 11(7):e1001685. PMC: 4114488. DOI: 10.1371/journal.pmed.1001685. View

14.

Talley A, Healy S, Finney O, Murphy S, Kublin J, Salas C . Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge. PLoS One. 2014; 9(11):e109654. PMC: 4236046. DOI: 10.1371/journal.pone.0109654. View

15.

Smith J . The role of PfEMP1 adhesion domain classification in Plasmodium falciparum pathogenesis research. Mol Biochem Parasitol. 2014; 195(2):82-7. PMC: 4159067. DOI: 10.1016/j.molbiopara.2014.07.006. View

16.

Jepsen M, Jogdand P, Singh S, Esen M, Christiansen M, Issifou S . The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. J Infect Dis. 2013; 208(3):479-88. DOI: 10.1093/infdis/jit185. View

17.

Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C . DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One. 2013; 8(2):e55571. PMC: 3573028. DOI: 10.1371/journal.pone.0055571. View

18.

Dutta S, Dlugosz L, Drew D, Ge X, Ge X, Ababacar D . Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog. 2014; 9(12):e1003840. PMC: 3873463. DOI: 10.1371/journal.ppat.1003840. View

19.

Laurens M, Thera M, Coulibaly D, Ouattara A, Kone A, Guindo A . Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS One. 2013; 8(11):e79323. PMC: 3832522. DOI: 10.1371/journal.pone.0079323. View

20.

Stoute J, Slaoui M, Heppner D, Momin P, Kester K, Desmons P . A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997; 336(2):86-91. DOI: 10.1056/NEJM199701093360202. View